Drug-Induced Liver Injury: Mechanisms, Types and Biomarkers

Author(s): M. Vinken, M. Maes, T. Vanhaecke, V. Rogiers

Journal Name: Current Medicinal Chemistry

Volume 20 , Issue 24 , 2013

Become EABM
Become Reviewer
Call for Editor


Drug-induced liver injury is a ubiquitous issue in clinical settings and pharmaceutical industry. Hepatotoxicity elicited by drugs may be intrinsic or idiosyncratic, both which are driven by different molecular mechanisms. Recently, a unifying mechanistic model of drug-induced liver injury has been introduced. According to this model, drug-induced hepatotoxicity relies on 3 consecutive steps, namely an initial cellular insult that leads to the occurrence of mitochondrial permeability transition, which in turn ultimately burgeons into the onset of cell death. Clinically, drug-induced liver injury can be manifested in a number of acute and chronic conditions, including hepatitis, cholestasis, steatosis and fibrosis. These pathologies can be diagnosed and monitored by addressing well-established physical, clinical chemistry and histopathological biomarkers. In the last few years, several novel read-outs of drug-induced liver injury have been proposed, involving genetic, epigenetic, transcriptomic, proteomic and metabolomic parameters. These new concepts and recent developments in the field of drug-induced liver injury are revised in the current paper.

Keywords: Biomarkers, drugs, hepatotoxicity, mechanisms, hepatitis, cholestasis, steatosis, fibrosis.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 30 June, 2013
Page: [3011 - 3021]
Pages: 11
DOI: 10.2174/0929867311320240006
Price: $65

Article Metrics

PDF: 184